Becton, Dickinson BDX
Healthcare · Medical - Instruments & Supplies · Synthos Deep Dive · 2026-07-03
The Overview
Becton, Dickinson (everyone calls it BD) makes the unglamorous but essential plumbing of healthcare: needles, syringes, IV catheters, infusion pumps, and the pre-filled injection systems drugmakers use. Hospitals buy these by the truckload, every day, forever — so the revenue is steady and predictable, like a toll road.
The stock is cheap — you're paying about $12.50 for every $1 of expected yearly profit, roughly half what the average big healthcare name costs. Why so cheap? Because the company barely grows (sales creep up low-single-digits), it carries a lot of debt, and it just spun off one of its divisions, so the story is messy right now.
Our verdict is Buy — Tactical: a bet that a beaten-down, dividend-paying cash machine bounces back as management cuts costs and buys back stock — not a bet on fast growth. If it works you make a solid, unspectacular return plus a ~2.4% dividend while you wait.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle). It's cheap and defensive (people always need syringes), which protects you — but the heavy debt and a stock that's already fallen 29% from its high mean it's not bulletproof.
- Growth Quality 4/10 (below average). A dependable business, but it grows slowly and earns only modest returns on the money it invests.
- Exponential Potential 2/10 (low). This will not double quickly. It's a mature, slow-and-steady name — own it for value and dividends, not fireworks.
The one big worry: BD owes a lot of money (~4 years' worth of profits in net debt). If growth disappoints, paying that down gets slow and the stock could stay stuck.
Putting a number on it: our fair-value estimate is $181 against a current price of $189.52 — a premium price for a business we still like.
Our summary metrics
Cheap (~12.5× fwd adj EPS) & defensive, but net-debt/EBITDA ~3.7–4× and a 29% drawdown temper the safety.
Low-single-digit revenue, ~7% forward adj-EPS CAGR, ~4% ROIC, goodwill-heavy — steady, not high quality.
Flat-to-slow top line, no acceleration, mature $44B medtech — this is a value/royalty, not an exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Flat-to-slow top line, no acceleration, mature $44B medtech — this is a value/royalty, not an exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $175 (high $204 / low $159; 16 Buy · 17 Hold · 1 Sell — "Hold") — context, not our anchor |
| Valuation | ~12.5× FY26E adj EPS · EV/EBITDA ~12.6× · P/S ~2.7× · P/FCF ~18× · div yield ~2.4% |
| Technicals | Neutral-to-repair — $158, −15% off 52-wk high, just above 50-DMA / near 200-DMA, RSI 64, +13% 12-mo (SPY +21%) |
| Conviction | Low — 1 net-bullish voice (we_study_billionaires, conviction 82), 1 reconciled claim; call is quant/value-led |
| Position sizing | Value satellite, ~2–3%; the re-rating is a thesis, not a certainty |
What the experts actually said 1 traceable claims on BDX · showing the highest-conviction voices
“After focusing on world-leading syringes/catheters (>50% share) plus spin-offs, BDX is an out-of-favor cash-generative 'royalty' at 12-13x earnings pricing in no growth.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $189.52, 14% above the 50-day average ($166), 19% above the 200-day average ($159) — an uptrend. 1% below the 52-week high of $192, 37% above the 52-week low of $139.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $189.52 is currently inside the band (band $169–$196).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 70.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.26, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = BDX · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Becton, Dickinson (NYSE: BDX) is a ~130-year-old global medical technology company — one of the largest makers of medical devices and single-use consumables in the world, with a dominant position in needles, syringes, IV/vascular access catheters, infusion systems (Alaris pumps), medication-management automation (Pyxis), pre-fillable drug-delivery systems for pharma, and peripheral/interventional vascular devices. Fiscal year ends September 30.
A structural note that dominates the current numbers: On February 9, 2026, BD completed the spin-off of its former Biosciences & Diagnostic Solutions ("Life Sciences") business and combined it with Waters Corporation. That business is now reported as discontinued operations, and prior periods have been recast. This is why the FMP FY2025 income statement still shows ~$21.8B revenue (three legacy segments) while the go-forward, continuing-operations run-rate is only ~$4.7B/quarter (~$19B/yr). Read the segment table below as legacy; the new BD reports four segments.
Revenue mix — the NEW post-spin structure (fiscal Q2'26, from the 8-K, continuing ops):
- Medical Essentials $1,647M (35%) · Interventional $1,357M (29%) · Connected Care $1,120M (24%) · BioPharma Systems $590M (13%). Growth was broad but modest: +1.7% to +5.3% FXN by segment.
- By geography (fiscal Q2'26): United States $2,917M (62%) · International $1,797M (38%). US-weighted, so exposed to US hospital capex and drug-pricing politics but also to US pricing power.
The strategic frame management pushes is "New BD": a leaner, four-segment medtech focused on margin expansion (the "BD Excellence" operating system), disciplined capital allocation (debt paydown + buybacks), and innovation in connected care and interventional.
2. The expert thesis — why the (thin) panel is constructive (traceable)
Honest breadth disclosure: the Synthos KB holds exactly ONE claim on BDX. This is a thinly covered name; the verdict is fundamentals- and quant-driven, with the single expert voice as corroboration, not the anchor.
- The value/"royalty" thesis — We Study Billionaires (
we_study_billionaires-v0t7eC-CHfQ:bdb13a9ba2, bullish, conviction 82, skill 1.0, 2026-04-11): "After focusing on world-leading syringes/catheters (>50% share) plus spin-offs, BDX is an out-of-favor cash-generative 'royalty' at 12-13x earnings pricing in no growth." This maps cleanly onto the data: a >50%-share consumables franchise, a completed portfolio-simplifying spin, ~12.5× forward earnings, and low-single-digit growth already in the price.
That is the whole panel. There is no high-breadth conviction stack here (contrast a name like LLY with 13 voices) — so we lean on the quant/value case and treat the single claim as confirming, not carrying, the call.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics:
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Cheap (~12.5× fwd adj EPS, ~2.4% yield) and defensive medtech demand cap the downside, but net-debt/EBITDA ~3.7–4× and a −29% drawdown from peak are real. Balanced, not bulletproof. |
| Growth Quality | 4 · Below-Average | Low-single-digit revenue, ~7% forward adj-EPS CAGR (mostly buybacks + margin, not volume), ROIC ~4% and ROE ~4.5%, goodwill/intangibles ~68% of assets. Steady cash, mediocre returns on capital. |
| Exponential Potential | 2 · Low | Flat-to-slow top line, negative second derivative is not the story — there just isn't acceleration, and a mature ~$44B cap against a slow-growth consumables TAM. A value/royalty, explicitly not a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path; the cases bound the range.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | "New BD" margin program + buybacks land; revenue re-accelerates to mid-single-digit; leverage falls toward 3×; multiple re-rates. FY27E adj EPS ~$14.5 on a ~16× multiple. | ~$232 (+47%) |
| Base (our anchor) | Guidance roughly holds — low-single-digit revenue, FY26 adj EPS ~$12.62 (mgmt guide $12.52–$12.72), FY27E ~$13.40; a cash-generative but slow compounder earns a modest ~13.5×. | ~$181 (+15%) |
| Bear | Hospital-capex softness or a pump/quality/regulatory setback; leverage constrains buybacks; multiple stays depressed. FY27E adj EPS ~$12 on ~10.5×. | ~$126 (−20%) |
Synthos fair value = the base case, ~$181 (+15%), with the full $126–$232 span as the honest range. This sits essentially on top of the Street's $175 consensus — a rare case where our modest, self-help-driven upside and the sell-side "Hold-with-a-target" line up. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). BDX is neither a high-return compounder nor an exponential — it is a mature value/royalty:
- Forward growth: continuing-ops revenue is guided to low-single-digit (FY26E ~$19.2B → FY30E ~$21.9B ≈ ~3.3%/yr CAGR on 4 analysts). Adjusted EPS CAGR is richer (~7% FY26→FY30E) but that is powered largely by buybacks and margin, not unit volume.
- Acceleration (the 2nd derivative): flat. There is no inflection — segment growth in the latest print ran +1.7% to +5.3% FXN. This is the opposite of the accelerating small-cap profile that scores high on this axis.
- Room to run: the consumables/medtech TAM is large but slow; at a ~$44B cap the constraint isn't size so much as the low structural growth rate of the end markets.
- Reinvestment runway: capex is light (~$0.76B, ~3.5% of sales) and FCF is healthy (~$2.7B FY25), but the cash is going to debt paydown and buybacks, not high-return organic reinvestment — appropriate given ~4% ROIC, but it caps the exponential case.
Exponential Potential: Low (2/10). Own BDX for a cheap multiple, a re-rating catalyst and a ~2.4% dividend — not for compounding fireworks. This honest framing is why it sits in the value-satellite sleeve, not the growth or Degen tiers.
5. Financials (real numbers — FMP annual/quarterly + the FY-Q2'26 8-K)
- Revenue: FY25 $21.84B (+8.2%) as historically reported (pre-recast, includes Life Sciences); go-forward continuing ops ~$19B/yr. Latest quarter (fiscal Q2'26) $4.71B, +5.2% reported / +2.6% FXN.
- Margins (continuing, adjusted): gross ~46% TTM, EBITDA margin ~22% TTM; adjusted diluted EPS $2.90 in fiscal Q2'26 (+3.9% YoY). Note the GAAP line was $(0.13) that quarter, dragged by discontinued-ops/separation charges and amortization — a reminder to read adjusted EPS here and treat it as management-defined.
- Earnings quality: GAAP net income $1.68B FY25 (as reported) with heavy D&A ($2.46B) and amortization of acquired intangibles — the GAAP-to-adjusted gap is large and structural (goodwill/intangibles ~68% of assets from the CareFusion/Bard/Embecta-era deals).
- Cash flow: operating CF $3.43B, capex −$0.76B, FCF ~$2.67B FY25 (FCF yield ~6% on ~$44B cap). This is the real anchor of the value case — the cash is genuine.
- Balance sheet — the pressure point: total debt $19.2B, cash $0.85B, net debt $18.3B, net-debt/EBITDA ~3.7× (FY25 EBITDA) / ~4× on continuing EBITDA. Current ratio 0.94. In fiscal Q2'26 management retired $2.1B of debt and ran a $2.0B accelerated share repurchase — the deleveraging-plus-buyback playbook is live, but leverage is still elevated for a slow grower.
6. Valuation — priced in or room?
BDX is genuinely cheap on every earnings-based lens: ~12.5× FY26E adjusted EPS (mgmt guide $12.52–$12.72), ~11.8× FY27E, EV/EBITDA ~12.6×, P/S ~2.7×, P/FCF ~18×, with a ~2.4% dividend on top. That is a low-to-mid-teens multiple for a >50%-share consumables franchise — the market is, as the KB voice puts it, "pricing in no growth."
The honest counterweight: cheap is deserved until proven otherwise. Returns on capital are low (~4% ROIC/ROE), growth is low-single-digit, and ~4× leverage means the equity carries financial risk. The re-rating case rests on self-help — margin (BD Excellence), buybacks shrinking the share count, and debt paydown lowering risk — rather than on demand. A reverse read: at ~12.5× the market demands almost nothing; even flat execution plus buybacks can nudge the multiple toward the mid-teens, which is most of our +15% base upside. Street targets (context): consensus $175, high $204, low $159 — our $181 base sits right in the pack. Not a growth buy; a cheap-cash-flow-with-a-catalyst buy.
7. Technicals (computed from EOD price history)
- Trend: neutral / repairing. $158.08 sits above the 50-DMA ($148) and just above the 200-DMA ($154) — a tentative recovery, not an established uptrend. MACD +1.73 (mildly positive).
- Location: −14.7% off the 52-week high ($185.39), +16.6% off the 52-week low ($135.54); max drawdown from peak −29% — this has been a laggard, not a leader.
- Momentum: RSI(14) 64 — firm but not overbought (<70).
- Relative strength (the tell): BDX +13.2% 12-mo vs SPY +20.6% and QQQ +30.3%; +1.1% 3-mo vs SPY +13.7%. Material underperformance — consistent with an out-of-favor value name, and part of why it's cheap.
- Read: technicals are stabilizing, not confirming. Price reclaiming the 200-DMA is constructive for a tactical entry, but the lagging relative strength says the market still needs proof. A hold of the 200-DMA (~$154) is the line to watch.
8. Moat & competitive position
BD's moat is scale + switching costs in consumables: >50% share in core syringes/catheters, deep hospital purchasing relationships, regulatory/qualification lock-in on devices used in clinical workflows, and a razor-and-blades installed base (Alaris pumps, Pyxis cabinets) that pulls recurring disposable revenue. It's a durable, wide-but-shallow moat — hard to displace, but in slow-growth end markets, and periodically exposed to device-quality/FDA risk (the Alaris infusion-pump saga is the cautionary precedent) and hospital-capex cyclicality.
Peer set (FMP-supplied, market cap): Edwards Lifesciences $54B, Alcon $34B, ResMed $30B, IDEXX $44B, Agilent $37B, IQVIA $35B, Veeva $31B, Cardinal Health $56B, Haleon $43B, argenx $58B. It's a mixed bag (some are higher-growth med-device/tools/CRO names); BDX screens as lower-growth and lower-multiple than most — the value end of the group. The truer comparables are large diversified device makers (Medtronic, Baxter, Stryker) not fully represented in this list.
9. Management, capital allocation & guidance
- Capital allocation: the current priority is balance-sheet repair + shareholder returns — fiscal Q2'26 alone saw a $2.0B accelerated share repurchase and $2.1B of debt retired, alongside a maintained dividend (~2.4% yield, ~$1.2B/yr). This is the correct playbook for a ~4%-ROIC, ~4×-levered cash generator, and it is the mechanical engine of the EPS-CAGR-above-revenue story.
- Insider activity: only small, routine officer sales in the sampled window (e.g., EVP dispositions of 75 and 1,100 shares in late June 2026, plus Form 3 initial-ownership filings) — no alarming cluster, nothing thesis-relevant.
- Management's own guidance (half-weighted — they talk their book): the fiscal Q2'26 8-K (2026-05-07) is a real earnings release and explicitly raised full-year FY26 adjusted-EPS guidance to $12.52–$12.72 (from $12.35–$12.65) while reaffirming low-single-digit revenue growth (FXN). CEO Tom Polen framed it as "revenue, margins and EPS all ahead of expectations… more than 90% of the business delivering mid-single-digit growth," crediting the "BD Excellence" margin program. Treated as management's self-interested words at half weight — but the raise is consistent with the base case and the leverage-reduction actions are verifiable, not just talk.
10. Catalysts & what to watch
- Next earnings: 2026-08-06 (fiscal Q3'26; Street EPS $3.14, revenue ~$4.89B). Watch organic (FXN) revenue growth by segment, adjusted margin trajectory, and the updated FY26 EPS/leverage print.
- Deleveraging pace: net-debt/EBITDA trending from ~4× toward ~3× is the single biggest de-risking catalyst — it directly supports a multiple re-rate.
- Buyback cadence: further ASRs shrinking the share count (post the $2.0B Q2 program).
- "New BD" margin delivery: proof that BD Excellence expands operating margin, not just adjusts it away from GAAP.
- Post-Waters clean-up: the first few "clean" continuing-ops quarters that let the market re-baseline the growth/margin profile.
Thesis tripwires (what would change the call): a device-quality/FDA action (pump precedent); FXN revenue turning negative; leverage rising instead of falling; or the adjusted-to-GAAP gap widening on new charges — any of which would move this from Tactical toward Watch.
11. Key risks
- Leverage (structural): ~$18.3B net debt, ~3.7–4× EBITDA against a low-single-digit grower — the dominant risk; it constrains buybacks and magnifies any earnings stumble.
- Low returns on capital: ~4% ROIC/ROE and ~68%-intangible asset base mean the business creates value slowly; the equity case leans on multiple + buyback, not compounding.
- Growth scarcity: if end markets or share soften, there's little organic growth to cushion, and "cheap" can stay cheap (value trap risk).
- Device-quality / regulatory: infusion-pump and consumable-device FDA exposure (Alaris precedent) is a recurring tail risk.
- Adjusted-vs-GAAP gap: heavy amortization and separation charges make GAAP earnings (fiscal Q2'26 GAAP EPS was negative) far below adjusted — investors must trust the adjustments.
- Thin expert coverage: only 1 KB claim — less independent corroboration than higher-conviction names; the call rests more on quant/value judgment.
12. Verdict, position sizing & monitoring
Buy — Tactical. BDX is a cheap (~12.5× forward adjusted EPS, ~2.4% yield), cash-generative (~$2.7B FCF), wide-moat consumables franchise that the market has left for dead after years of sluggish growth and a portfolio-simplifying Waters spin. The tactical upside is a self-help re-rating — margin (BD Excellence), a live buyback ($2.0B ASR), and debt paydown ($2.1B retired in one quarter) lifting a depressed multiple even on low-single-digit revenue. Our base case ($181, +15%) lines up with the Street ($175), and the single expert voice (we_study_billionaires, conviction 82) corroborates the "out-of-favor royalty" framing.
- Sizing: value satellite, ~2–3% — a re-rating bet with a dividend to wait on, not a core compounder. The ~4× leverage and low ROIC cap how much conviction the numbers support.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, with deleveraging pace the key metric. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $158.08.
- Single biggest risk: leverage meeting sluggish growth — if deleveraging stalls, the re-rating thesis stalls with it, and cheap stays cheap.
Provenance & disclosures
- Traceability: 1 KB claim, breadth 1, skill 1.0 (
we_study_billionaires), last claim 2026-04-11 — reconciled to a realclaim_id(cited inline). This is a thinly covered, quant/value-driven call; fabricated conviction is structurally impossible (claim-ID reconciliation). - Data as-of: fundamentals 2026-03-31 (fiscal Q2'26) · estimates & prices 2026-07-02/03 · expert claim 2026-04-11. Forward figures are analyst consensus / management guidance (FMP + SEC 8-K), labeled as estimates.
- Structural caveat: the Life Sciences spin (into Waters, 2026-02-09) makes FMP's legacy segment/revenue blocks stale; go-forward figures use continuing operations and the four New-BD segments.
- Management caveat: BD's raised FY26 adj-EPS guidance ($12.52–$12.72) is management's own book, half-weighted by design; the associated debt-paydown and buyback actions are verifiable.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").